Benzinga | Aug 6, 2021 07:42AM EDT

Barclays Maintains Overweight on BioCryst Pharmaceuticals, Raises Price Target to $21

Barclays analyst Gena Wang maintains BioCryst Pharmaceuticals (NASDAQ:BCRX) with a Overweight and raises the price target from $20 to $21.